Influence of cognitive impairment on cardiac mortality after percutaneous coronary intervention in very elderly

Tomoko Tomioka1, Ryokichi Takahashi1, Yosuke Ikumi1

  • 1Department of Cardiology, South-Miyagi Medical Center, Miyagi, Japan.

Insights

Cognitive impairment (CI) significantly increases cardiac mortality in very elderly patients undergoing percutaneous coronary intervention (PCI). Social support, like living with a partner, also impacts cardiac outcomes after PCI.

Area of Science:

  • Cardiology
  • Geriatrics
  • Neurology

Background:

  • Cognitive impairment (CI) is linked to higher cardiac mortality in the very elderly.
  • Percutaneous coronary intervention (PCI) is a strategy to reduce cardiac mortality in ischemic heart disease (IHD).

Purpose of the Study:

  • To investigate the impact of cognitive impairment (CI) on cardiac mortality following percutaneous coronary intervention (PCI) in very elderly patients.

Main Methods:

  • Retrospective analysis of 95 IHD patients over 80 years old who underwent PCI (2012-2014).
  • Patients were screened for CI using the Mini-Mental State Examination.
  • Comparison of cardiac mortality and adverse cardiac events between CI and non-CI groups over a 3-year follow-up.

Main Results:

  • Cardiac mortality was significantly higher in the CI group (36%) versus the non-CI group (13%).
  • CI was identified as an independent cardiac prognostic factor post-PCI.
  • For patients with CI, living with a partner with CI independently predicted cardiac death within three years.

Conclusions:

  • Cognitive impairment (CI) significantly worsens cardiac prognosis after PCI in very elderly individuals.
  • Social factors, such as living situation, are crucial for improving patient outcomes post-PCI.
  • Integrating social background assessment with medical management can enhance cardiac prognoses.
Abstract

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
162
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
191
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
210
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
169
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
179
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
191